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Purpose Area under the curve (AUC) dosing is routinely carried out for carboplatin,
but the chosen target AUC values remain largely empirical. This multicenter
pharmacokinetic-pharmacodynamic (PK-PD) study was performed to determine the
covariates involved in the interindividual variability of carboplatin hematotoxicity
that should be considered when choosing individual target AUCs.Patients and
Methods Three hundred eighty-three patients received carboplatin as part of
established regimens. A semi-physiologic population PK-PD model was applied to
describe separately the time course of absolute neutrophil and platelet counts using
NONMEM software. The plasma ultrafiltrable carboplatin concentration (CCarbo)
was assumed to inhibit the proliferation of blood cell precursors through a linear
model: drug effect = slope × CCarbo. The slope corresponds to the patients'
sensitivity to carboplatin hematotoxicity. The relationships between the patients'
sensitivity to the neutropenic or thrombopenic effects of carboplatin and various
covariates, including associated chemotherapies, demographic, biologic, and
pharmacogenetic data, were studied. Results The sensitivity of carboplatin-induced
thrombocytopenia decreased in the case of concomitant paclitaxel chemotherapy
(slope decreased by 24%), whereas it increased with coadministration of etoposide
and gemcitabine (slope increased by 45% and 133%, respectively). For neutropenia,
the sensitivity increased when carboplatin was combined with other cytotoxics (slope
increased by 76%). Conclusion This study provides useful information to clinicians to
better estimate the hematopoietic toxicity of carboplatin and thus choose more
rationally carboplatin target AUCs as a function of pretreatment or concomitantly
administered chemotherapies. For example, an AUC of 5 mg/mL · min is associated
with a risk of grade 3 or 4 thrombocytopenia of 2% in combination with paclitaxel
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